Delivery Order SPE2DB20D3101-SPE2DB22FK3J7
Award Date 7/7/22
Potential Completion Date 7/8/22
Potential Value $4.6K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order contract to Amerisourcebergen Drug Corp's Corporate Office Division, a subsidiary of Amerisourcebergen Corporation, for the supply of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML pharmaceutical product. The $33,745.79 firm fixed price contract has an ultimate completion date of April 18, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and DLA Troop Support Medical, valued up to $999,999,999.00...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,437.19, is a Firm Fixed Price Delivery Order for the supply of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML. The contract has an ultimate completion date of February 12, 2025 and was awarded on February 11, 2025. This contract award is part of a larger Indefinite Delivery Contract (IDC) valued at...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,540.37, is for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a specialty pharmaceutical product. This is a delivery order contract, with a firm fixed-price pricing type, and an ultimate completion date of December 18, 2024. The contract does not have a set-aside designation, indicating open...
- This federal contract award is for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on December 5, 2024, with a ceiling value of $12,729.15 and a completion date of December 6, 2024. This is a delivery order contract with a firm fixed price pricing type. The contract is not designated with a set-aside requirement,...
- This federal contract award is for the delivery of REBIF REBIDOSE 44 MCG/0.5 ML 0.5ML, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The $8,206.68 firm-fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of July 30, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the...
- This federal contract award, valued at $4,664.50, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a specialty medication. The award is a delivery order under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which is valued at $999,999,999 and runs through November 2026. This IDC serves as a primary vehicle for...
- This federal contract award, valued at $12,303.90, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the provision of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a specialty medication. The contract has an ultimate completion date of October 21, 2024 and does not have a set-aside designation, indicating open competition. Amerisourcebergen, the prime contractor, is a...
- This federal contract award is for the delivery of Rebif 44 mcg/0.5 mL syringes to the Defense Logistics Agency (DLA). The award, valued at $6,179, was made to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc. The IDC, valued at up to $999,999,999, is the primary vehicle for Cencora, Inc. to provide a comprehensive...
- This federal contract award is for the delivery of the pharmaceutical product REBIF 44 MCG/0.5 ML SYRINGE 0.5ML to the Defense Logistics Agency (DLA), a defense agency. The $18,675.71 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor. The contract has an ultimate completion date of June 4, 2024 and does not have a set-aside designation. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC)...
- The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order contract valued at $23,476.91 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML. This order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 through December 31, 2025 between Amerisourcebergen and DLA Troop Support Medical. The IDC enables DLA to efficiently procure a comprehensive range of pharmaceutical products and...